U.S. regulators defend requiring more data on monkeypox drug


4 August 2022 - As U.S. monkeypox cases rise, U.S. health agencies in a medical journal article published on Wednesday defended their decision to require human trial data to show that SIGA Technologies' experimental drug TPOXX is safe and effective to treat the virus.

U.S. agencies have been under pressure to ease access to the medicine, which is being distributed by the U.S. Centers for Disease Control and Prevention under a special "compassionate use" access that requires doctors to request it from the agency or their health department and enrol each patient in a study.

Read Reuters article

Michael Wonder

Posted by:

Michael Wonder